PCSK9
Selected indexed studies
- Oral PCSK9 Inhibitors. (Curr Atheroscler Rep, 2024) [PMID:38536608]
- PCSK9-directed therapies: an update. (Curr Opin Lipidol, 2024) [PMID:38277255]
- Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. (Nature, 2020) [PMID:33177715]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Oral PCSK9 Inhibitors. (2024) pubmed
- PCSK9-directed therapies: an update. (2024) pubmed
- Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. (2020) pubmed
- Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside. (2024) pubmed
- PCSK9 as an Atherothrombotic Risk Factor. (2023) pubmed
- PCSK9 inhibitors: a patent review 2018-2023. (2024) pubmed
- PCSK9: A novel inflammation modulator in atherosclerosis? (2019) pubmed
- PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis. (2024) pubmed
- PCSK9: A emerging participant in heart failure. (2023) pubmed
- PCSK9: from biology to clinical applications. (2019) pubmed